MSC Therapy for Lupus Nephritis: 120-Patient Study Shows 57% Renal Response at 12 Months
A 2026 real-world study followed 120 refractory lupus nephritis patients treated with UC-MSCs. Cumulative renal response reached 56.7% at 12 months with low relapse rates and zero severe adverse events. Here’s what clinicians need to know.
Read More »